Abstract
The discovery that human papillomavirus (HPV) is the necessary causal factor in cervical carcinogenesis has made it a target for prophylactic and therapeutic vaccines, as well as a diagnostic tool in cervical screening. Whilst prophylactic vaccination has proven very effective in terms of preventing cervical cancer precursor lesions, therapeutic strategies have presented far greater challenges. HPV testing has shown itself to be extremely valuable in the triage of low grade cytological abnormalities, test of cure following treatment of cervical intraepithelial neoplasia (CIN), and will, over the next 10 years, gradually replace cytology as the mainstay of primary cervical screening. In this review, the latest evidence supporting HPV as both a biomarker of risk for cervical cancer and a target for prophylactic and therapeutic vaccination is presented. © 2012 Informa UK Ltd All rights reserved.
Original language | English |
---|---|
Pages (from-to) | 478-488 |
Number of pages | 10 |
Journal | International Journal of Hyperthermia |
Volume | 28 |
Issue number | 6 |
DOIs | |
Publication status | Published - Sept 2012 |
Keywords
- Cervarix
- Cervical cancer
- Cervical screening
- Gardasil
- HPV
- HPV test
- Human papillomavirus
- Prophylatic vaccine
- Therapeutic vaccine